123 filings
Page 4 of 7
8-K
do5qeg4v3b
18 Aug 20
Submission of Matters to a Vote of Security Holders
5:23pm
8-K
40b50
10 Aug 20
Wave Life Sciences Reports Second Quarter 2020 Financial Results and Provides Business Update
7:38am
8-K
vqy80sym7 v2i7xa
11 May 20
Wave Life Sciences Reports First Quarter 2020 Financial Results and Provides Business Update
7:36am
8-K
ahgir
23 Apr 20
Other Events
5:16pm
8-K
mlgs ppotny5u
14 Apr 20
Entry into a Material Definitive Agreement
5:15pm
8-K
5c3dj4l t3jo6
2 Mar 20
Wave Life Sciences Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update
6:54am
8-K
k8g1ajs2f
6 Feb 20
Cost Associated with Exit or Disposal Activities
4:04pm
8-K
merzg18n1e
13 Jan 20
Regulation FD Disclosure
7:03am
8-K
u7uzcrqsgyy
10 Jan 20
Departure of Directors or Certain Officers
4:53pm
8-K
29w 464uuh
30 Dec 19
Wave Life Sciences Announces Topline Data and Addition of Higher Dose Cohort in Ongoing Phase 1b/2a
8:45am
8-K
ox060e8usso
16 Dec 19
Wave Life Sciences Announces Discontinuation of Suvodirsen Development for Duchenne Muscular Dystrophy
7:10am
8-K
92me aldchrppd
5 Nov 19
Wave Life Sciences Reports Third Quarter 2019 Financial Results and Provides Business Update
12:00am
8-K
5xb7grf rp6df
7 Oct 19
Regulation FD Disclosure
4:47pm
8-K
n60 9bxqhdxuj
5 Sep 19
Wave Life Sciences Expands Board of Directors with Three New Appointments
7:35am
8-K/A
xnn9 hvueq
16 Aug 19
Submission of Matters to a Vote of Security Holders
12:00am
8-K
i8b19sa
14 Aug 19
Submission of Matters to a Vote of Security Holders
12:00am
8-K
irda8
29 Jul 19
Wave Life Sciences Reports Second Quarter 2019 Financial Results and Provides Business Update
4:11pm
8-K
32pqng
5 Jun 19
Regulation FD Disclosure
7:58am
8-K
vpvc ahe2jjpsztt
10 May 19
Wave Life Sciences Reports First Quarter 2019 Financial Results and Provides Business Update
8:15am
8-K
l7cs l2080h
16 Apr 19
Wave Life Sciences Announces Suvodirsen Phase 1 Safety and Tolerability Data and Phase 2/3 Clinical Trial Design
8:28am